Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cash & Equivalents: 2009-2022

Historic Cash & Equivalents for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to $60.7 million.

  • Avadel Pharmaceuticals' Cash & Equivalents rose 4.38% to $60.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $60.7 million, marking a year-over-year increase of 4.38%. This contributed to the annual value of $50.7 million for FY2021, which is 29.30% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Cash & Equivalents of $60.7 million as of Q3 2022, which was up 12.17% from $54.1 million recorded in Q2 2022.
  • Avadel Pharmaceuticals' 5-year Cash & Equivalents high stood at $102.2 million for Q2 2020, and its period low was $9.3 million during Q4 2018.
  • Over the past 3 years, Avadel Pharmaceuticals' median Cash & Equivalents value was $60.9 million (recorded in 2022), while the average stood at $67.4 million.
  • Per our database at Business Quant, Avadel Pharmaceuticals' Cash & Equivalents slumped by 76.46% in 2019 and then skyrocketed by 663.30% in 2020.
  • Avadel Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $9.3 million in 2018, then rose by 4.82% to $9.8 million in 2019, then soared by 633.80% to $71.7 million in 2020, then dropped by 29.30% to $50.7 million in 2021, then rose by 4.38% to $60.7 million in 2022.
  • Its last three reported values are $60.7 million in Q3 2022, $54.1 million for Q2 2022, and $60.9 million during Q1 2022.